Advanced Cancer Detection Solutions For First Responders
A Better Way to Screen for Cancer—
Built for Firefighters
Cancer is a leading cause of line-of-duty deaths among firefighters. Firefighters are up to 2x more likely to develop certain cancers compared to the general population. Early detection is critical—and now, it’s easier than ever with EPISEEK®, the fast, affordable, and accurate cancer screening test. Unlike other MCED tests, EPISEEK detects all presumptive cancer types including brain cancer.
We’ve Partnered with Front Line Mobile Health
We are delighted to partner with Front Line Mobile Health to deliver advanced cancer screening in the states of Texas, Georgia, and Colorado.
Why Firefighters Trust EPISEEK
Quick Results
Just a simple blood draw with results in 7–10 days
Early Detection
Helps catch cancer before symptoms appear
First Responder Discount
Special pricing for fire departments and individuals
Unmatched Coverage
The only screening test detecting the 10 deadliest cancers—including brain
The EPISEEK Test
Detects All Major Cancer Types
Bladder
Brain
Breast
Colon & Rectum
Esophagus & Oral
Kidney
Myeloma & Leukemia
Liver/Biliary
Lung & Bronchus
Lymphoma
Pancreas
Prostate
Stomach
Thyroid
Uterine, Cervical & Ovarian
Who Should Get Tested?
EPISEEK is appropriate for the following:
- Firefighters and first responders with substantial occupational related risk
- Individuals 45 years and older
- Individuals with elevated cancer risk
Not recommended for pregnant individuals or those planning to become pregnant in the next three months, those under 21, or anyone currently undergoing active cancer treatment.
Take the First Step Toward Prevention
Add EPISEEK to your screening routine today and take advantage of exclusive rates for first responders.
Using a specificity of 99.5%, EPISEEK is predicted to have a positive predictive value (PPV) of 64.9% and a negative predictive value (NPV) of 99.5% in patients 50 years and older.
For aggressive stages I and II cancers that do not have widely adopted screening—such as bladder, esophagus, head and neck SCC, lung, pancreas, and uterine—EPISEEK has a sensitivity of 62%. At stage III, which is still operable in many cases, the sensitivity for aggressive cancers is 80%.